Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOCICEPT: Accelerated TMS, D-Cycloserine, and Therapy for Depression and Trauma
NCT07868627Phase 2Active, not recruiting
- Sponsor
- McLean Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised trial of d-cycloserine in major depressive disorder (MDD), anxiety disorder and psychological trauma (4 arms), sponsored by McLean Hospital. Primary endpoints: Patient Health Questionnaire 9 at 3 months, Generalized Anxiety Disorder-7 at 3 months and 1 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)anxiety disorderpsychological trauma
Beyond the preview
Go deeper on NCT07868627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07868627.